Organization · Venture Capital
HighCape Capital
HighCape Capital is a growth equity fund based in the United States, specializing in the Life Sciences sector. The firm partners with innovative companies to enhance their commercial and operational strategies.
Overview
What HighCape Capital does
What HighCape Capital is
HighCape Capital is a growth equity fund based in the United States, specializing in the Life Sciences sector. The firm partners with innovative companies to enhance their commercial and operational strategies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2013
- Approximate age
- About 13 years
- Structured capabilities
- Funder
- Last reviewed
- March 26, 2026
Official channels
Find HighCape Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
HighCape Capital as a funder
Investment thesis
HighCape Capital invests in innovative Life Sciences companies at early revenue or product launch stages, focusing on Connected Health, Medical Devices, and Biotechnology. The firm partners closely with management teams to enhance their commercial and operational strategies.
Focus narrative
HighCape Capital invests in the Life Sciences sector, specifically in areas such as Connected Health, Medical Devices/Tools, and Biotechnology. The organization employs a hands-on approach to partner with management teams, enhancing their commercial and operational strategies.
Value beyond capital
HighCape Capital adds value to its portfolio companies by actively partnering with management teams to enhance their commercial and operational strategies, leveraging the team's extensive industry experience and network to facilitate growth and successful exits.
Terms and economics
- Typical check
- $1,000,000–$10,000,000
- Sweet spot
- $5,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Sectors
- Biotech · Healthcare · Medical Devices · Digital Health
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
- Recorded notable exits
- TELA Bio and Quantum-Si
Portfolio context
HighCape Capital has invested in several notable companies, including: Cybrexa Therapeutics: A biotech company focused on developing innovative cancer therapies. Alphina Therapeutics: A company involved in therapeutic development. Modifi Biosciences: A biotech firm that was acquired by Merck in 2024. Cheetah Medical: Leader in non-invasive cardiac output and hemodynamic monitoring. TELA Bio: Specializes in surgical reconstruction and soft tissue repair; went public (NASDAQ: TELA). Quantum-Si: Focuses on next-gen proteomics via semiconductor chips; went public via SPAC in 2021 (NASDAQ: QSI).
Common questions
What to know about HighCape Capital
Upseed classifies HighCape Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.